DB17162InvestigationalProtein Based Therapies
ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors, while delivering enhanced...
- Mechanism
- Curator reviewed
Pharmacologically active on Programmed cell death 1 ligand 1 and Tumor necrosis factor receptor superfamily member 9
- Code names
- ATG-101
Resolves to
Compound
Targets
What you can answer from here — as of July 19, 2026
Which drugs share a target with ATG-101, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account